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Abstract
With regard to rheumatoid arthritis, remission as currently used in
the literature can have two meanings: either a state with persistent
absence of clinical and radiological signs of disease activity with-
out being treated for a specific time period, or it may point to a
disease state with minimal disease activity during antirheumatic
treatment. A risk factor for the first is absence of autoantibodies,
with the anti-CCP-antibodies as best predictors, whereas risk
factors for achieving a drug-induced state of minimal disease
activity are not well defined. These definitions of remission refer to
different disease states; therefore, we propose that the term
remission is reserved for patients that are not treated with
antirheumatic drugs.
Introduction
Since it was first named by Sir AB Garrod in his treatise of
1859 [1], rheumatoid arthritis (RA) has been considered a
chronic disease, which implies that the curing of it or
longstanding remission from it is an uncommon course of the
disease. Although remission has always been the ultimate goal
of treatment, during the times of the pyramid treatment strategy
the prevalence of remission was low and the main effect of
therapy was to slow the progression of the disease. The
observation that even patients with low disease activity exhibit
an increase in disability as well as radiographic progression has
prompted the rheumatological community to perform trials that
have shown that tight control of disease activity is the best way
to prevent disability [2]. The availability of more aggressive
treatment strategies, including the use of biologics, has
increased the ability to achieve remission. This has pressed
rheumatologists to reconsider the description of a remission.
Within the concept of remission, two clinical states must be
separated (Figure 1). First, remission can be defined as a
state in which there is absence of disease activity without any
concomitant use of drugs, which seems compatible with the
curing of RA. This state necessitates the absence of clinical
evidence for arthritis and no progression of radiological
damage during a specific time period without the use of
disease modifying antirheumatic drugs (DMARDs). Today, this
form of remission is achieved by only a small percentage of
patients and is either drug-induced or the result of the natural
disease course (natural remission). Patients with a pure
natural remission have never been treated with DMARDs.
Second, the term remission is often used to describe a
disease state in which RA patients have a (very) low disease
activity while using DMARDs. In this case, remission is
considered as a disease state at the lower end of the
continuum of disease activity and signifies that a patient is
optimally treated. The present article reviews the currently
used definitions for, and characteristics associated with, these
different disease states with a focus on recent-onset arthritis.
Natural remission
Recent-onset arthritis bears the inherent problem that
classification of the disease is difficult [3]. In an analysis of the
first 1,000 patients included in the Leiden Early Arthritis Clinic
at 2 weeks, only 10% fulfilled the criteria for RA, and a about a
third of the patients presented with an undifferentiated arthritis
(UA) [4]. From several inception cohort studies it is known that
some of these UA patients remit spontaneously, some (about
one-third) develop RA and the rest remain undifferentiated or
develop other rheumatological diagnoses [4].
The development of RA seems to be a multistage process, in
which a number of genetic and environmental factors trigger
the development of UA and a subsequent amount of triggers
is required for progression towards RA (Figure 2). The
number and the identity of the triggers needed for the
development of RA are only partly known, but the chance to
remit spontaneously is lower in established RA than in UA. It
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must be realised that in the literature there is no accepted
definition or classification criterion for natural remission. Thus,
the observed prevalence of natural remission depends on the
definition that is chosen, the setting (community or hospital)
or patient population (UA or RA) and the duration of follow-
up. In this perspective, it is relevant to emphasize important
data from population-based studies from the 1960s (reviewed
in [5]) in which a profound difference was observed in
patients in clinical settings compared to population-based
settings. Intriguingly, it was observed that RA identified in
population-based settings is often a self-limited process
because in the group of individuals with RA that were
reviewed 3 to 5 years later, RA could still be observed in only
about 30% of them, indicating the relevance of the setting for
the frequency of natural remission.
Natural remission in undifferentiated arthritis
Harrison and colleagues [6] defined natural remission as the
absence of arthritis at physical examination after cessation of
DMARDs, including steroids, for at least 3 months. In this
study, 358 patients with early arthritis that were included in
the Norfolk Arthritis Register were examined; assessing the
subgroup of patients that presented with UA revealed that
42% of them had achieved natural remission after 2 years
follow-up [6]. A group of 112 patients with UA was followed
in Birmingham, UK, and after one year a remission rate
(defined as complete resolution of symptoms) of 55% was
found [7]. Van Aken and colleagues [8] studied the first
1,064 patients with an early arthritis that were included in the
Leiden Early Arthritis Cohort. At presentation, 330 patients
had an UA and after one year follow-up about one-third of
these patients was in remission (persistent absence of
arthritis at examination) and, therefore, were discharged from
the outpatient clinic [8]. In a study including 100 patients with
UA (Leeds, UK) a lower remission rate was observed in
comparison with the above-mentioned studies [9]. Remission
(absence of symptoms in patients receiving no treatment)
was observed in 13% after 1 year follow-up [9]. In conclu-
sion, the frequency of natural remission in UA seems to vary
between 13% and 55%.
Risk factors for natural remission in
undifferentiated arthritis
Both Harrison and colleagues [6] and Tunn and Bacon [7]
performed logistic regression analyses to identify factors that
were independently associated with natural remission.
Although the number of swollen joints, male gender [6] and
the absence of rheumatoid factor [7] were recognized as
independent predictive variables to achieve a natural
remission, the explained variability of these analyses was too
low to result in a model that, in UA patients, adequately
predicts the chance to remit spontaneously [6,7]. Notably,
the presence of HLA class II alleles, in particular DR4, was
associated with persistency of disease [10].
Figure 1
Different clinical states that are indicated as remission in the current
literature. The ‘cure’ state necessitates the absence of clinical
evidence for arthritis and no progression of radiological damage during
a specific time period without the use of disease modifying
antirheumatic drugs. In the ‘disease state with low disease activity’
definition of remission, treatment with disease modifying antirheumatic
drugs is allowed and this points to a disease state at the lower end of
the continuum of disease activity and signifies that a patient is optimaly
treated.
Figure 2
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A recent analysis using early arthritis patients included in the
Leiden Early Arthritis Cohort revealed that, of a total of 1,700
patients, 570 patients had an UA at inclusion and that, after
1 year of follow-up, 150 patients (26%) were discharged
from the outpatient clinic because of the repeated absence of
signs and symptoms of arthritis. Assessing clinical and
serological characteristics in a logistic regression analysis
with the presence/absence of remission as dependent
variable revealed that the number of swollen joints, the
absence of anti-cyclic citrullinated peptide (CCP) antibodies
and the level of sedimentation rate were independently
associated with the chance to achieve a remission
(unpublished data, Van der Helm-van Mil). Also in this
analysis, however, the fraction of explained variance was low
and the three independent predictive variables had
insufficient discriminative ability to be used in clinical practice
for the identification of the patients with a high risk to achieve
a natural remission. It is intriguing that the original observation
of Salmon and colleagues from 1993 [10] is reproduced and
explained by our recent data from 2005/2006. In fact, HLA
class II alleles such as DR4 that form the ‘shared epitope’ are
not primarily a risk factor for RA but for the presence of CCP
antibodies [11,12]. With respect to the population-based
cohorts studied in the 1960s, a similar observation was made.
Rheumatoid factor was observed in only about 20% to 30%
of the patients and these individuals were characterized by
persistent disease [5]. In summary, the absence of anti-CCP
antibodies is a strong risk factor for natural remission in UA.
Natural remission in rheumatoid arthritis
The rate of natural remission in patients with RA is evidently
lower compared to patients with UA. In 1985, Wolfe and
colleagues [13] investigated 458 patients with RA that were
followed for 1,131 patient years. Of these patients, 14%
achieved remission without being treated. In addition, in
1996, Prevoo and colleagues [14] described a cohort of 227
early RA patients with a median follow-up of 4 years and
remission was observed in 9.5% of them. In a Swedish
cohort of 183 RA patients with a follow-up of 5 years, a
remission rate of 20% was described; 11% had a natural
remission and 9% was drug-induced [15]. Linn-Rasker and
colleagues [16] examined 285 RA patients and found that
remission (in the absence of DMARDs for at least 1 year) was
achieved in 10% of patients after a mean disease duration of
4.6 years. Some of the patients included in this study had
been treated with DMARDs before achieving remission,
although this involved mild drugs, such as penicillamine and
hydroxychloroquine, which are expected to have little potency
to induce a remission. A number of clinical characteristics
between the patients that did and did not enter remission
were compared, and only the presence of anti-CCP
antibodies was associated with a lower risk to achieve
remission [16]. In the above-mentioned studies, remission
was defined by the absence of clinical characteristics. In a
Finish study, the prevalence of radiological remission during
an impressive follow-up period of 20 years was assessed;
102 rheumatoid factor positive, erosive RA patients were
included and radiological remission (absence of radiological
progression measured using the Larsen score) was found in
26% of patients [17]. However, some of the patients still had
swollen joints at the time of the radiological remission, and
the absence of both arthritis and radiological progression
was observed in 19% of patients after a disease duration of
20 years [17]. In this study, the baseline ESR and number of
swollen joints were not significantly associated with the
chance of remission, the autoantibody status was not
described, and a lower rate of joint destruction at inclusion
did correlate with a higher percentage of remission [17].
In conclusion, the prevalence of natural remission in RA is
reported to be about 10% and the absence of anti-CCP
antibodies is correlated with natural remission in RA.
Drug-induced remission in rheumatoid arthritis
The effect of stopping DMARD therapy (several second line
drugs but no tumour necrosis factor (TNF) inhibitors) in RA
patients with a good long-term therapeutic response was
assessed in a 52 week, randomised, double-blind, placebo-
controlled study [18]. The 285 patients either continued the
second-line drug (n = 142) or received a placebo (n = 143);
the endpoint was a flare defined as recurrence of arthritis. At
the study entry patients had been treated with DMARDs
during (median) 5 years and at 52 weeks the cumulative
incidence of a flare differed significantly between the placebo
group (38%) and the continued therapy group (22%). The
same trend was found for each second-line drug separately
(antimalarial, parenteral gold, sulphasalazine, or metho-
trexate), with the exception of d-penicillamine [18]. As the
participants of this study were RA patients that already had
low disease activity during therapy, the rate of drug-induced
remission in the general population of RA patients cannot be
deduced from it. Disease characteristics significantly
associated with a flare were, in logistic regression analysis,
the presence of rheumatoid factor and swollen joints [18].
Risk factors for natural or drug-induced
remission in rheumatoid arthritis
Characteristics associated with natural or drug-induced
remission in RA are the absence of anti-CCP antibodies/
rheumatoid factor, a low number of swollen joints and a low
level of radiological joint destruction at baseline [16-18].
Some genetic risk factors for RA, PTPN22 and HLA class II
alleles, have been investigated in relation to the development
of remission in RA. The absence of the PTNP22 T allele (risk
allele) was not associated with a higher level of remission
[19]. Also, the presence of the HLA alleles that encode the
amino acids DERAA, which are associated with a lower odds
ratio to develop RA and a milder disease course, did not
induce a higher risk to achieve remission [20]. The shared
epitope that includes HLA alleles was significantly less often
present in the patients that achieved remission compared to
the patients with persistent RA [20]; however, after
Available online http://arthritis-research.com/content/8/4/216correction for the presence of anti-CCP antibodies, there was
no association between HLA and remission, and only the
absence of anti-CCP antibodies was independently
correlated with the chance to remit spontaneously.
Remission used to indicate a state of low
disease activity
To guide clinicians in evaluating treatment responses in daily
practice and to define remission in clinical trials, standardized
measures for remission have been formulated by the
American College of Rheumatology (ACR), the European
League against Rheumatism (EULAR) and the US Food and
Drug Administration (FDA). The ACR criteria for remission
include six core variables, of which five must be fulfilled for at
least two consecutive months. These include fatigue, joint
pain, joint tenderness, joint swelling, duration of morning
stiffness, joint swelling, and ESR [21]. The EULAR response
criteria use an index of disease activity (the disease activity
score (DAS)), which is determined by a mathematical formula
[22] (Table 1). The initial DAS counted 44 joints on swelling
and included the Ritchie articular index for tender joints. The
DAS28 uses an abbreviated 28-joint count for tender and
swollen joints, omitting, among others, the feet [22]. Using
the original DAS (44 joints), low disease activity is defined by
a score between 1.6 and 2.4, and remission is defined by a
score below 1.6. When the DAS28 is applied, a score
between 2.6 and 3.2 indicates low disease activity, and a
score lower than 2.6 points to remission. In a Spanish
random sample of 788 RA patients, the positive predictive
value of each of the DAS28 indices was assessed: the
positive predictive value for remission of a normal ESR was
7%, of morning stiffness <15 minutes 8%, of the absence of
fatigue 9%, of the absence of joint tenderness 13%, of the
absence of joint swelling 16% and of the absence of joint
pain by anamnesis 28% [23]. The FDA has formulated the
most rigorous definition for remission. These guidelines
require that the ACR criteria for remission are met in addition
to a radiological arrest (Sharp-van der Heijde or Larsen
method) over a period of six following months in the absence
of DMARDs [24]. Two less stringent response criteria were
also formulated, complete clinical response and major clinical
response [24]; according to this classification, complete
clinical response is similar to remission while continuing
antirheumatic therapy (Table 1).
It has been argued that the ACR criteria for remission are
difficult to apply for clinical trials, as patients do not easily
fulfill these criteria due to the time requirement of two months
Arthritis Research & Therapy    Vol 8 No 4 van der Helm-van Mil et al.
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Table 1
Definition of remission as treatment outcome/disease state in RA
Remission criteria Definition
ACR criteria For clinical remission, a minimum of five of the following items must be present for at least two subsequent months:
Morning stiffness <15 minutes
No fatigue
No joint pain by history
No joint tenderness or pain on motion
No soft-tissue swelling in joints or tender sheats
ESR <30 mm/1st hour in women or <20 mm/1st hour in men
Disease activity  DAS remission defined as a score <1.6 using a compound index of the following measures:
score criteria Ritchie articular index of tender joints
44 swollen joint count
ESR
Patient’s assessment of general health (measured on a 100 mm visual analogue scale)
DAS28 remission defined as a score <2.6 using a compound index of the following measures:
28-joint count for tender and swollen joints
ESR
Patient’s assessment of general health
FDA criteria Remission
Requires achieving ACR clinical remission and absence of radiological progression (Larsen or Sharp-van der Heijde 
method) over a continuous 6 month period in the absence of DMARDs
Complete clinical remission
Same as remission, but while continuing DMARD therapy
Major clinical response
Requires achieving ACR70 response for at least 6 subsequent months (ACR70 response means 70% improvement of 
tender and swollen joint count coupled with improvement in 3 of 5 of the following: patient’s assessment, physician’s 
assessment, ESR or CRP, pain scale, Health Assessment Questionnaire)
The formula to calculate the DAS is: 0.54 × √ Ritchie articular index + 0.065 × 44swollen joint count + 0.33 × ln ESR + 0.0072 × general health.
The formula to calculate the DAS28 score is: 0.56 × √ 28tender joint count + 0.28 × √ 28swollen joint count + 0.7 × lnESR = 0.014 × general
health.and the inclusion of fatigue. Therefore, most recent trials
currently use a DAS-based definition of remission or use the
ACR70 response criteria. However, the ACR70 response
criteria are not an adequate measure for remission as the
concordance between ACR70 and DAS remission is low and
ACR70 responders have a higher number of tender or
swollen joints or ESR than patients in DAS remission [25].
Several studies have compared the DAS-defined remissions
with the ACR criteria for remission or the DAS remission with
remission according to the DAS28. Although it is reported
that a DAS28 <2.6 corresponds to the ACR remission
criteria [26], a recent report showed that DAS remission is
more conservative than DAS28 remission and concludes that
a DAS28 cutoff of 2.6 has insufficient validity to use in clinical
trials [27]. A Finish comparison of remission according to the
DAS28 and ACR criteria showed that a DAS cutoff value of
2.3 corresponds to the ACR criteria and that, even among
patients with a DAS <2.3, tender joints were present in 19%,
swollen joints in 11% and both swollen and tender joints in
7% [28]. The FDA clinical response criteria include a time
requirement of six months; the percentage of patients
achieving remission according to this definition is lower than
the percentages when remission was assessed at one time
point [25]. This time requirement seems relevant given data
that show that when remission is based on a single time
measurement disease progression can occur [29]. The most
likely explanation for this observation is that either subclinical
disease is present or the waxing and waning disease activity
of a low disease activity state is measured at the lowest level
thereby creating ‘false-positive remissions’.
In conclusion, the DAS and ACR criteria are both an
important outcome measure for treatment response in clinical
trials. The ACR and FDA criteria contain a time constraint that
results in a lower percentage of remissions in comparison
with the assessment of remission at one time point.
Obviously, a time constraint in the definition of remission
leads to less ‘false-positive’ findings of remission in patient
management. Therefore, in our opinion, the presence of a time
condition in the definition of remission enhances the
significance of the remission for use as an outcome measure
in clinical trials, and when a DAS-based definition of
remission is used, the study should consider repeating it over
time in order to calculate the mean and standard deviation of
the disease activity.
Remission used to indicate a state of low
disease activity in rheumatoid arthritis
A number of studies have used the ACR criteria for remission
or a DAS-based definition. In a study with a 3 year follow-up,
ACR remission while using methotrexate was observed in 7%
of patients and in 9% while treated with the combination of
methotrexate, cyclosporine A and sulfasalazine [30]. After
treatment for 48 weeks with cycosporin A monotherapy, ACR
remission was achieved in 7% of patients and in 10% after
the combined treatment with cyclosporine A and metho-
trexate [31]. Also, the COBRA trial used the ACR definition
for remission (modified, with the fatigue criterion excluded)
and observed a remission rate of 28% after 28 weeks of
combined treatment with methotrexate, sulfasalazine and
prednisone. However, almost all remissions ended after
prednisone was stopped [32]. Investigating the disease
outcome in RA patients treated with leflunomide showed a
DAS28 remission in 13% after 6 months [33].
It is interesting to note that the remission rates while being
treated with DMARDs are comparable with the reported
natural remission rates in RA; both clinical states are
described to occur in about 10% of the RA patients. How-
ever, the remissions under antirheumatic treatment are
generally more rapidly achieved and, with the currently
available data, the cumulative level of joint destruction can not
be easily compared. As an alternative wording for ‘state of
low disease activity’, one may consider the wording ‘drug-
requiring remission’. Given the fact that it is not known
whether the patients with drug-induced remission differ from
the patients with ‘drug-requiring low disease activity’, we
propose the wording ‘disease state with low disease activity’
for this patient group.
Risk factors for a state of low disease activity
in rheumatoid arthritis
The clinical or serological risk factors for achieving an ACR- or
DAS-defined remission while being treated with DMARDs are
not well defined. Intriguingly, while the presence of anti-CCP
antibodies is unambiguously associated with persistency of joint
inflammation, the absence or presence of autoantibodies in RA
is not reported to be a powerful factor in predicting treatment
responses. In a trial in which subanalysis has been reported, the
presence of anti-CCP antibodies was associated with a higher
chance to achieve a low disease activity state [34].
Can early and aggressive treatment increase
the rate of (drug-induced) remission in RA?
An intriguing question is whether the now available anti-
rheumatic treatment strategies can increase the percentage
of RA patients that achieve a remission with the absence of
both clinical signs of arthritis and progression of joint destruc-
tion that persists after the treatment has been stopped (drug-
induced remission). A disease state formulated like this
closely resembles the FDA definition of remission and might
be regarded as ‘cure’ of the disease. In other words, since a
small amount of RA patients (about 10%) remits naturally in
the absence of treatment, the query now is whether current
antirheumatic therapies are able to increase this number of
patients, are capable of shortening the time period to achieve
this remission and can reduce the level of joint destruction at
the moment of remission.
The most effective treatment strategies at present are most
likely the combination of TNF inhibitors with other DMARDs.
For the combination of etanercept with methotrexate, a
Available online http://arthritis-research.com/content/8/4/216
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the 2-year time point [35]. While using the combination of
infliximab (6 mg/kg) with methotrexate, 31% of patients
remitted (DAS28) after a follow-up of 54 weeks in the study
of St Clair and colleagues [36]. In addition, in the BeSt study,
treatment with infliximab and methotrexate combined with a
tight control of treatment efficacy (DAS-based treatment
adjustments every 3 months), resulted in a DAS remission in
56% of patients after 13 months of treatment; these patients
continued with methotrexate monotherapy without the need
to restart infliximab in the subsequent months. The use of
adalimumab together with methotrexate induced a remission
rate (DAS28) of 49% after 2 years of treatment [37]. Although
the combined use of TNF inhibitors with methotrexate is
evidently more effective in achieving minimal disease activity
compared to DMARD monotherapy, the question whether
these patients remain in remission after the cessation of
therapy still needs to be determined.
Conclusion
Remission as an outcome measure of an observational study
or clinical trial can have different meanings. It may concern a
clinical state with persistent absence of clinical and
radiological signs of disease activity without being treated for
a specific time period. This remission might be drug induced,
but can, in a small percentage of RA patients, also be
achieved naturally. The RA patients that remit spontaneously
are extremely interesting, as studying these patients in
relation with risk factors might increase the understanding of
the processes that are involved in remission/disease
persistency. Remission may also point to a disease state with
(very) low disease activity during treatment with DMARDS;
this state of minimal disease activity is generally measured
using the ACR criteria or the DAS. For reasons of clarity, we
propose that these meanings of remission are not mixed and
that the term remission is reserved for patients that are not
being treated with DMARDs. In contrast, the patients with a
low disease activity during antirheumatic therapy should be
denoted as having minimal disease activity. The fact that
these two states should not be mixed is further illustrated by
the different risk factors for each state. Absence of anti-CCP
antibodies is the best risk factor for achieving natural
remission in both UA and early RA, whereas the risk factors
for treatment responses and a state of low disease activity
are not yet clear. Whether the currently available treatment
strategies for RA are able to increase the percentage of
remissions in RA will become evident in the next decade.
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